Vor Biopharma Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. Vor is a clinical-stage cell and genome engineering company focused on hematological malignancies. It had no approved products and generated no revenue.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $12.9 million | $8.1 million | $34.8 million | $20.3 million |
| General and administrative | $5.7 million | $3.6 million | $15.9 million | $7.4 million |
| Total operating expenses | $18.6 million | $11.8 million | $50.7 million | $27.7 million |
| Net loss | $18.6 million | $11.8 million | $50.6 million | $27.7 million |
| Net loss per share, basic and diluted | $0.50 | $61.23 | $1.62 | $177.84 |
Margins are not meaningful because the company had no revenue. Loss per share comparisons are not directly comparable: the 2021 periods reflect the IPO and conversion of preferred shares, while the 2020 figures reflect a much smaller weighted-average common-share base and preferred-stock dividends.
- Cash and investments: $226.0 million at September 30, 2021, comprising $143.0 million of cash and cash equivalents and $82.9 million of investments. Restricted cash equivalents were an additional $2.4 million.
- Cash flow, nine months: $51.6 million used in operations; $85.7 million used in investing, primarily investment purchases; and $232.6 million provided by financing. Cash, cash equivalents and restricted cash increased $95.3 million.
- Balance sheet: Total assets were $258.6 million, total liabilities $25.7 million, and stockholders’ equity $233.0 million. No debt was outstanding. Lease liabilities totaled $17.6 million.
- Margins and profitability: The company reported operating and net losses and expects significant losses to continue; it has an accumulated deficit of $111.9 million.
Changes versus prior comparable periods
- Q3 net loss increased by $6.8 million year over year; nine-month net loss increased by $23.0 million. Higher R&D and G&A spending drove the increases.
- Nine-month R&D expense rose $14.5 million, primarily from higher personnel costs, preclinical and research costs, clinical program costs, and facilities expense. G&A rose $8.5 million, mainly from headcount, professional fees and insurance.
- Financing substantially increased liquidity: Vor received $45.4 million from the final Series B preferred-stock tranche and completed its February 2021 IPO. The IPO generated approximately $186.3 million in net proceeds as described by the company. Preferred stock converted into common stock at the IPO closing.
- Investment holdings increased to $82.9 million from none at year-end 2020. The company also invested $2.7 million in property and equipment during the first nine months.
Outlook, commentary and risks
- Management estimated that cash, cash equivalents and investments at September 30, 2021 would fund operating expenses and capital needs into approximately mid-2023. The filing cautions that this estimate depends on assumptions and capital may be exhausted sooner. The notes separately state resources were sufficient for at least one year after issuance of the financial statements.
- Vor expected R&D and G&A expenses to increase as it advances clinical programs, expands facilities and manufacturing capabilities, hires staff, and incurs public-company costs. It expects no product revenue in the near future, if ever, and anticipates needing additional capital.
- The VOR33 Phase 1/2a trial was actively enrolling; the company said it was on track to report initial clinical data in the first half of 2022. COVID-19 had contributed to site-activation delays, and further effects on enrollment, vendors, supply chains and timelines remained uncertain.
- Vor expected to submit an IND for the VOR33/VCAR33 treatment system in the second half of 2022, subject to results from the VOR33 trial and the investigator-sponsored VCAR33 trial. FDA acceptance of comparability or data-reference claims for VCAR33 was uncertain.
- Significant risks include the early, unvalidated nature of engineered stem-cell technology; clinical, safety and regulatory uncertainty; dependence on VOR33 and VCAR33; third-party manufacturing and licensed intellectual property; competition; and the need for further financing. The filing describes potential gene-editing, transplant and CAR-T safety risks, including off-target effects and serious adverse events.
- Two June 2021 lease amendments add approximately 40,437 square feet, with estimated commencement in Q1 2022. The company disclosed $30.6 million of fixed payments not yet included on the balance sheet; the amendments also required a $2.4 million letter of credit secured by restricted cash.
- After quarter-end, on November 8, 2021, Vor amended its Columbia license to add intellectual property rights and up to $2.0 million in additional commercial milestone payments for one additional product. The company reported no material legal proceedings and no material change in internal control over financial reporting.
Key facts for investors to verify
- Whether VOR33 enrollment and the stated first-half 2022 initial-data timeline progressed as planned, and the clinical results and safety profile.
- Whether VCAR33 trial data become available and whether FDA accepts the proposed comparability and data-reference approach.
- Actual cash burn, investment liquidity and updated runway versus management’s mid-2023 estimate, including the impact of trial, hiring, manufacturing and lease costs.
- Future financing needs and potential dilution, given no product revenue and expected ongoing losses.
- Progress on manufacturing capacity, third-party supply, and the additional Columbia license terms and milestone obligations.